BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS  The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease  FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
BC Week In Review | Jan 4, 2019
Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in Japan, Korea and Taiwan to develop BPN14770 to treat brain disorders associated with dementia, including Alzheimer's disease and...
BC Week In Review | Dec 8, 2017
Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45 healthy elderly volunteers showing that twice-daily 10 and 20 mg oral doses of Alzheimer's disease candidate BPN14770 for...
BC Week In Review | Jan 18, 2016
Clinical News

BPN14770: Phase I started

Tetra began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners LLC , Grand Rapids, Mich.   Product: BPN14770   Business: Neurology...
BC Extra | Dec 31, 2015
Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770 , the first candidate funded by NIH's Blueprint Neurotherapeutics Network (BPN) to reach the clinic. The negative allosteric modulator of phosphodiesterase-4D ( PDE-4D ) is...
Items per page:
1 - 6 of 6